GO
Loading...

Eli Lilly and Co

More

  • Midday Glance: Pharmaceuticals companies Wednesday, 17 Sep 2014 | 1:17 PM ET

    Baxter International Inc. fell $2.17 or 2.9 percent, to $72.82. Johnson& Johnson rose$. 01 or percent, to $105.89. Eli Lilly& Co. rose$. 01 or percent, to $65.81.

  • Early Glance: Pharmaceuticals companies Wednesday, 17 Sep 2014 | 10:29 AM ET

    Baxter International Inc. fell $1.33 or 1.8 percent, to $73.66. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $50.99. Hospira rose$. 09 or. 2 percent, to $53.34.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • Final Glance: Pharmaceuticals companies Tuesday, 16 Sep 2014 | 7:46 PM ET

    Baxter International Inc. rose$. 44 or. 6 percent, to $74.99. Bristol-Myers Squibb Co. rose $1.20 or 2.4 percent, to $51.15. Hospira rose$. 46 or. 9 percent, to $53.25.

  • Midday Glance: Pharmaceuticals companies Tuesday, 16 Sep 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 40 or. 5 percent, to $74.95. Bristol-Myers Squibb Co. rose$. 74 or 1.5 percent, to $50.69. Hospira rose$. 30 or. 6 percent, to $53.09.

  • Early Glance: Pharmaceuticals companies Tuesday, 16 Sep 2014 | 10:43 AM ET

    Baxter International Inc. rose$. 25 or. 3 percent, to $74.80. Bristol-Myers Squibb Co. rose$. 16 or. 3 percent, to $50.11. Hospira rose$. 01 or percent, to $52.80.

  • Lilly, AstraZeneca team up on Alzheimer's drug Tuesday, 16 Sep 2014 | 10:36 AM ET

    INDIANAPOLIS— Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

  • NEW YORK, Sept 16- U.S. stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U.S. interest rates.

  • US STOCKS-Futures dip ahead of data, Fed eyed Tuesday, 16 Sep 2014 | 7:33 AM ET

    *The Labor Department's producer price index, due at 8:30 a.m. EDT, is expected to have risen 0.1 percent in August, the same as in July.

  • *Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.

  • Final Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 15 or. 2 percent, to $74.55. Bristol-Myers Squibb Co. fell$. 31 or. 6 percent, to $49.95. Hospira rose$. 16 or. 3 percent, to $52.79.

  • Midday Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 1:24 PM ET

    Baxter International Inc. fell$. 31 or. 4 percent, to $74.39. Bristol-Myers Squibb Co. fell$. 32 or. 6 percent, to $49.95. Hospira rose$. 18 or. 3 percent, to $52.81.

  • Early Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 10:37 AM ET

    Baxter International Inc. fell$. 40 or. 5 percent, to $74.30. Bristol-Myers Squibb Co. fell$. 27 or. 5 percent, to $49.99. Johnson& Johnson fell$. 05 or percent, to $104.53.

  • Final Glance: Pharmaceuticals companies Friday, 12 Sep 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 39 or. 5 percent, to $74.70. Bristol-Myers Squibb Co. fell$. 42 or. 8 percent, to $50.26. Hospira fell$. 36 or. 7 percent, to $52.63.

  • Midday Glance: Pharmaceuticals companies Friday, 12 Sep 2014 | 1:19 PM ET

    Baxter International Inc. fell$. 43 or. 6 percent, to $74.66. Bristol-Myers Squibb Co. fell$. 40 or. 8 percent, to $50.28. Hospira fell$. 35 or. 7 percent, to $52.64.

  • Early Glance: Pharmaceuticals companies Friday, 12 Sep 2014 | 11:13 AM ET

    Baxter International Inc. fell$. 26 or. 3 percent, to $74.83. Bristol-Myers Squibb Co. fell$. 12 or. 2 percent, to $50.56. Hospira fell$. 07 or. 1 percent, to $52.92.

  • Sept 12- Eli Lilly and Co's Cyramza stomach-cancer drug prolonged survival of patients with advanced colon cancer in a late-stage study, the U.S. drugmaker said on Friday. The 1,000- patient global study, called RAISE, involved patients who had previously failed to adequately benefit from Roche Holding AG's Avastin and other standard treatments.

  • Lilly cancer drug fares well in late-stage study Friday, 12 Sep 2014 | 10:38 AM ET

    INDIANAPOLIS— Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.

  • Midday Glance: Pharmaceuticals companies Thursday, 11 Sep 2014 | 2:09 PM ET

    Baxter International Inc. fell$. 19 or. 2 percent, to $75.10. Bristol-Myers Squibb Co. fell$. 42 or. 8 percent, to $50.66. Hospira fell$. 16 or. 3 percent, to $53.00.

  • Early Glance: Pharmaceuticals companies Thursday, 11 Sep 2014 | 10:29 AM ET

    Baxter International Inc. fell$. 28 or. 4 percent, to $75.00. Bristol-Myers Squibb Co. fell$. 26 or. 5 percent, to $50.82. Hospira fell$. 03 or. 1 percent, to $53.12.